Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Bauernhofer, T; Pichler, M; Wieckowski, E; Stanson, J; Aigelsreiter, A; Griesbacher, A; Groselj-Strele, A; Linecker, A; Samonigg, H; Langner, C; Whiteside, TL.
Prolactin receptor is a negative prognostic factor in patients with squamous cell carcinoma of the head and neck.
Br J Cancer. 2011; 104(10):1641-1648 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Aigelsreiter Ariane
Bauernhofer Thomas
Griesbacher Antonia
Groselj-Strele Andrea
Langner Cord
Linecker Alexander
Pichler Martin
Samonigg Hellmut
Altmetrics:

Dimensions Citations:

Plum Analytics:
Number of Figures: 4
| | | |
Abstract:
BACKGROUND: The influence of human prolactin (hPRL) on the development of breast and other types of cancer is well established. Little information, however, exists on the effects of hPRL on squamous cell carcinomas of the head and neck (SCCHNs). METHODS: In this study, we evaluated prolactin receptor (PRLR) expression in SCCHN cell lines and assessed by immunohistochemistry the expression in 89 patients with SCCHNs. The PRLR expression was correlated with clinicopathological characteristics as well as clinical outcome. The effect of hPRL treatment on tumour cell growth was evaluated in vitro. RESULTS: Immunoreactivity for PRLR was observed in 85 out of 89 (95%) tumours. Multivariate COX regression analysis confirmed high levels of PRLR expression (>25% of tumour cells) to be an independent prognostic factor with respect to overall survival (HR = 3.70, 95% CI: 1.14-12.01; P = 0.029) and disease-free survival (P = 0.017). Growth of PRLR-positive cancer cells increased in response to hPRL treatment. CONCLUSION: Our data indicate that hPRL is an important growth factor for SCCHN. Because of PRLR expression in a vast majority of tumour specimens and its negative impact on overall survival, the receptor represents a novel prognosticator and a promising drug target for patients with SCCHNs. British Journal of Cancer (2011) 104, 1641-1648. doi: 10.1038/bjc.2011.131 www.bjcancer.com Published online 19 April 2011 (C) 2011 Cancer Research UK
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Aged -
Aged, 80 and over -
Carcinoma - genetics
Carcinoma, Squamous Cell -
Cell Line, Tumor -
Disease-Free Survival -
Female -
Head and Neck Neoplasms - genetics
Humans -
Immunohistochemistry -
Male -
Middle Aged -
Neoplasm Recurrence, Local - genetics
Neoplasm Staging -
Neoplasms, Squamous Cell - genetics
Prognosis -
Prolactin - pharmacology
Receptors, Prolactin - biosynthesis

Find related publications in this database (Keywords)
prolactin receptor
head and neck cancer
prognosis
growth factor
proliferation
© Meduni Graz Impressum